For centuries, stories claimed that young blood could restore youth—from vampire legends to ancient rituals. Now, cutting-edge science suggests there might be truth to the tale. Researchers at Beiersdorf AG, the skincare giant behind brands such as NIVEA and Eucerin, have demonstrated that components in young human blood serum can restore youthful properties to aging skin—but only when bone marrow cells are involved.
In the research report, published in Aging, the study authors note that “Our results provide first evidence that systemic factors exert rejuvenating effects on the skin exclusively in the presence of bone marrow-derived cells.”
Recreating Youth in the Lab
The team used a sophisticated microphysiological system (MPS), also known as an organ-on-a-chip, to simulate human circulation between two 3D models: one of full-thickness skin and one of bone marrow, complete with stem cells that generate blood cells. They introduced serum from young donors (under age 30) or older donors (over age 60) into this system, mimicking earlier heterochronic parabiosis experiments in which the circulatory systems of young and old animals were combined.
The results were striking. Young serum alone had no effect on skin rejuvenation. But in the presence of bone marrow cells, it triggered those cells to secrete a suite of proteins that revitalized the skin model. The bone marrow model “showed a significant increase of progenitor cells together with a significant decline of granulocytes and an improved mitochondrial membrane potential in response to treatment with young human serum,” the researchers reported.
The Protein Messengers of Youth
Through proteomic analysis, the team identified 55 potential rejuvenating proteins produced by bone marrow-derived cells in response to young serum. Seven stood out for their ability to boost skin cell renewal, collagen production and mitochondrial energy output while reducing signs of cellular aging.
These proteins, the researchers believe, act as messengers—translating the chemical signals in young blood into physical changes in the skin. Without bone marrow’s involvement, the skin never “heard” the rejuvenation message.
Why Bone Marrow Matters
Bone marrow is more than a blood factory. It harbors hematopoietic and mesenchymal stem cells along with progenitor cells that secrete cytokines, growth factors and other molecules critical for immune function, wound healing and tissue repair. In youth, these cells are highly active and responsive. With age, however, they lose potency, produce more inflammatory molecules and contribute to skin thinning, wrinkling and slower healing.
By exposing aged bone marrow cells to young serum, the researchers effectively reawakened their regenerative potential—resulting in skin tissue that appeared and behaved biologically younger. Epigenetic age clocks, which measure DNA methylation patterns linked to biological age, confirmed that treated skin exhibited a measurable reduction in age.
From Vampire Myths to Vanity Tables
While this research is still preclinical, the implications are significant. The anti-aging skincare industry is already a booming sector, projected to reach $381.2 billion by 2032. The study suggests the possibility of developing a new class of topical or injectable treatments based on proteins derived from bone marrow.
There is precedent: platelet-rich plasma (PRP) treatments, which use a patient’s own blood to stimulate collagen production, are already popular in dermatology. But isolating specific proteins that drive true rejuvenation could be far more targeted and powerful.
Further research will be needed to identify safe and effective ways to deliver these proteins and to confirm their benefits in clinical trials. But the researchers are optimistic. By pinpointing the molecular drivers of skin rejuvenation, they have opened a door to regenerative strategies that could one day slow the signs of aging.
Did you enjoy this blog post? Check out our other blog posts as well as related topics on our Webinar page.
QPS is a GLP- and GCP-compliant contract research organization (CRO) delivering the highest grade of discovery, preclinical, and clinical drug research development services. Since 1995, it has grown from a tiny bioanalysis shop to a full-service CRO with 1,200+ employees in the US, Europe, Asia, India and Australia. Today, QPS offers expanded pharmaceutical contract R&D services with special expertise in pharmacology, DMPK, toxicology, bioanalysis, translational medicine, cell therapy (including PBMCs, leukopaks and cell therapy products), clinical trial units and clinical research services. An award-winning leader focused on bioanalytics and clinical trials, QPS is known for proven quality standards, technical expertise, a flexible approach to research, client satisfaction and turnkey laboratories and facilities. Through continual enhancements in capacities and resources, QPS stands tall in its commitment to delivering superior quality, skilled performance and trusted service to its valued customers. For more information, visit www.qps.com or email info@qps.com.
